Rob Etherington is the CEO and President of Clene Nanomedicine, Inc. Clene is a privately held early-stage biopharmaceutical company, based in Salt Lake City, Utah, with technical research & development and manufacturing in Havre de Grace, Maryland. Clene was founded in December 2012. Clene is focused on therapeutic nanosuspensions with potential application in diseases of neurology, oncology, and immunology. Clene closed its Series A capital fundraising in April 2015 at an oversubscribed aggregate amount of $31.6M. Rob has held a variety of roles over his 23 years in the pharmaceutical industry. Rob is the former senior vice president in charge of commercial operations at Actelion Pharmaceuticals US, Inc, which he joined in its founding year of commercialization as its first marketing officer. During his 13-year tenure at Actelion, Rob presided over the commercialization activities as Actelion grew into a $12+ billion market-cap company with annual sales of nearly $2 billion across its portfolio of approved drugs, including Opsumit and Tracleer (2000-2013). Rob also served as an officer of Actelion Pharmaceuticals US, Inc, and on the US Executive Board. Before joining Actelion, Rob served as a marketing leader at Pfizer (Parke-Davis Division, Warner-Lambert Company) with key responsibilities in the launch years for Lipitor and Rezulin. Rob is an alumnus of the Harvard Business School General Management Program, and he holds an MBA from the Marriott School at Brigham Young University.